At the inception stage, the twin goals of the Thal-AIM project are to develop an assessment tool to rule out Thalassemia Major incidence in young kids at an early stage and to develop a module to evaluate and track the risk of mortality for adult patients under other clinical management via AI-based system implementation in cloud-based SAS. The product is intended for use in diagnostic clinics, by patients, and in hospitals.

Every year, approximately 10 000-15 000 babies are born with Thalassemia Major (TM). Early bone marrow transplantation (BMT) is the most appropriate treatment. Another important aspect of management is regular blood transfusion, which is expensive and carries a mortality risk due to iron deposits in organs and associated complications. The product is intended for use in diagnostic clinics, by patients, and in hospitals. It also connects the dots to enable a seamless care service in India to meet the patient's needs and can be integrated with the GOI's RBSK programme.